New Peer-Reviewed Publication in Therapeutic Advances in Chronic Disease Features Nymox NX-1207 Drug for BPH
September 26 2011 - 10:07AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the
publication of a new peer-reviewed paper in Therapeutic Advances in
Chronic Disease featuring NX-1207, the Company's innovative
treatment for benign prostatic hyperplasia (BPH). NX-1207 is
currently in Phase 3 trials in the U.S. The paper, "The potential
for NX-1207 in benign prostatic hyperplasia: an update for
clinicians" is written by Neal Shore MD FACS, Medical Director of
the Carolina Urologic Research Center, Myrtle Beach, SC and Barrett
Cowan MD FACS of Urology Associates PC, Englewood, CO. Dr. Shore
and Dr. Cowan are well known experts in urology and have
participated as clinical investigators in clinical trials of
NX-1207 as well as in multiple follow-up studies of the drug. The
paper is available online at
http://taj.sagepub.com/content/early/2011/09/23/2040622311423128.abstract.
In Authors Opinions, the authors write: "The authors have both
participated as clinical investigators in the NX-1207 trials, and
have found the administration of the drug to be a quick and
uncomplicated procedure which takes a few minutes only, and which
can be easily done by urologists, most of whom do very similar
injections on a routine basis (e.g. during prostate biopsy and
prostate infiltrations). There is no need for any new or special
equipment, and no special training will be required.
Compared to existing oral drug therapies (alpha blockers and
5-alpha reductase inhibitors), the use of NX-1207 does not have
daily and lifelong compliance issues or the concerns of
polypharmacy facing the aging population as well as the risk for
drug-drug interactions. In addition, NX-1207 has not shown any of
the bothersome and limiting sexual side effects of the oral
therapies (such as impotence, loss of libido, or retrograde
ejaculation)."
NX-1207 is a novel patented drug developed by Nymox which is
currently in Phase 3 trials. The drug has successfully completed a
series of blinded controlled multi-center U.S. clinical trials
where a single dose of NX-1207 has been found to produce
symptomatic improvements about double that reported for currently
approved BPH drugs without causing the sexual or cardiovascular
side effects associated with those drugs. Follow-up studies have
shown evidence of long lasting benefit with a significant
proportion of men who received a single dose reporting maintained
improvement in BPH symptoms for up to 7 ½ years.
BPH treatment represents a growing market with more than 100
million men worldwide being estimated to suffer from BPH symptoms.
The disorder is a common affliction of older men, affecting
approximately half of men over age 50 and close to 90% of men by
age 80, and is associated with growth in prostate size as men
age.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024